Capillary electrophoresis with electrochemiluminescence detection for the simultaneous determination of cisatracurium besylate and its degradation products in pharmaceutical preparations.

Capillary electrophoresis with electrochemiluminescence detection for the simultaneous analysis of cisatracurium besylate and its degradation products (laudanosine, quaternary monoacrylate) in pharmaceutical preparation was developed and fully validated. The significant parameters that influence capillary electrophoresis separation and electrochemiluminescence detection were optimized. The total analysis time of the analytes was 15 min. The linearities of the method were 0.1∼40.0 µg/mL for cisatracurium besylate and 0.04∼8.00 µg/mL for laudanosine, with correlation coefficients (r) of 0.999 and 0.998, respectively. The detection limits (S/N = 3) were 83.0 ng/mL for cisatracurium besylate and 32.0 ng/mL for laudanosine. The intraday relative standard deviations of the analytes were <3.0%, and the interday relative standard deviations were <8.0%. The developed method was cost-effective, sensitive, fast, and resource-saving, which was suitable for the ingredient analysis in pharmaceutical preparation.

[Simultaneous determination of tryptophan and its metabolites in plasma by high performance liquid chromatography with on-column derivatization].

A high performance liquid chromatography-ultraviolet/fluorescence detection (HPLC-UV/FLD) with on-column derivatization was established to simultaneously determine tryptophan (Trp), kynurenine (Kyn), 5-hydroxyindole acetic acid (5-Hiaa) and kynurenic acid (Kyna). A Hypersil C-18 column (250 mm x 4.0 mm, 5 microm) was used for the analysis at 30 degrees C. The separation was carried out with the mobile phase consisting of 250 mmol/L zinc acetate (pH 5.5) and acetonitrile (95: 5, v/v) at a flow rate of 0.8 mL/min using 3-nitrotyrosine as internal standard (IS). The excitation (Ex) and emission (Em) wavelengths were set at 278 nm (lambda(ex))/343 nm (lambda(em)) for 5-Hiaa and 244 nm (lambda(ex))/400 nm (lambda(em)) for Kyna, while the wavelengths of ultraviolet detection were set at 360 nm for Kyn and IS, 302 nm for Trp. The recoveries were in the range of 91.62% to 114.17%. The linearities were from 2.50 micromol/L to 320.00 micromol/L for Trp, 0.32 micromol/L to 15.36 micromol/L for Kyn, 3.27 nmol/L to 104.60 nmol/L for 5-Hiaa, and 14.00 nmol/L to 464.80 nmol/L for Kyna. The detection limits were 0.078 micromol/L, 0.056 micromol/L, 0.690 nmol/L and 1.290 nmol/L for Trp, Kyn, 5-Hiaa, and Kyna, respectively. Thirty plasma samples of normal pregnant women and 28 plasma samples of healthy controls were tested, and the results exhibited that the concentrations of Trp, Kyn and Kyna in the plasma of the normal pregnant women were significantly different from those of the control group (all P < 0.01). The method is simple and sensitive with good reproducibility, and it is suitable for clinical measurements.

[Determination of homocysteine in plasma by precolumn derivatization-high performance liquid chromatography with fluorescence detection].

A precolumn derivatization-high performance liquid chromatographic method for the determination of homocysteine (Hcy) in plasma was established. Tris (2-carboxyethyl) phosphine hydrochloride (TCEP) and N-(1-pyrenyl) maleimide (NPM) were used as the reduced reagent and derivatization reagent, respectively. The separation was carried out on an Agilent Hypersil C-18 column (250 mm x 4.0 mm, 5 microm) in gradient elution mode. The mobile phase consisted of A (15 mmol/L sodium acetate solution), B (acetonitrile) and C (300 mL water containing 1 mL acetic acid and 1 mL phosphoric acid). The eluate was monitored by the fluorescence detector at an excitation wavelength of 330 nm and an emission wavelength of 380 nm. The mean recovery of Hcy was (102.08 +/- 4.94)%. The linear range was from 0.500 micromol/L to 100 micromol/L, with a detection limit of 0.016 micromol/L. The intra-day and inter-day relative standard deviations (RSDs) for Hcy were less than 5%. Seven plasma samples of patients with hypertension and seven plasma samples of healthy controls were tested, and the results demonstrated that the Hcy in the plasma from the hypertension group was significantly different from that of the control group (p < 0.05). The developed method is simple, fast, accurate, and suitable for clinical measurement.